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tween tube thoracostomy (with or without fibrinolytics) and 
thoracoscopy. Open surgical intervention is sometimes re-
quired to control pleural sepsis or to restore chest mechan-
ics. This review gives an overview of parapneumonic effu-
sion and empyema, focusing on recent developments and 
controversies.  Copyright © 2008 S. Karger AG, Basel 
 Introduction and Definitions 
 At least 40% of all patients diagnosed with pneumonia 
will have an associated pleural effusion, although the mi-
nority of these will require active intervention  [1, 2] . A 
parapneumonic pleural effusion refers to any effusion 
secondary to pneumonia or lung abscess  [1] . It becomes 
‘complicated’ when an invasive procedure is necessary 
for its resolution, or if bacteria can be cultured from the 
effusion  [1] . Empyema is a term derived from the Greek 
verb  empyein (‘to suppurate’) and literally refers to frank 
pus in the pleural space. Parapneumonic effusion and 
empyema remain important medical conditions associ-
ated with significant morbidity and mortality  [2] . It is 
estimated that in the United States alone, pleural infec-
tions have an incidence of 60,000 per year and a mortal-
ity of approximately 15%  [3, 4] . Yet, controversy remains 
regarding the management and specifically the role of 
fibrinolytic therapy. 
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 Abstract 
 At least 40% of all patients with pneumonia will have an as-
sociated pleural effusion, although a minority will require an 
intervention for a complicated parapneumonic effusion or 
empyema. All patients require medical management with 
antibiotics. Empyema and large or loculated effusions need 
to be formally drained, as well as parapneumonic effusions 
with a pH  ! 7.20, glucose  ! 3.4 mmol/l (60 mg/dl) or positive 
microbial stain and/or culture. Drainage is most frequently 
achieved with tube thoracostomy. The use of fibrinolytics 
remains controversial, although evidence suggests a role for 
the early use in complicated, loculated parapneumonic effu-
sions and empyema, particularly in poor surgical candidates 
and in centres with inadequate surgical facilities. Early tho-
racoscopy is an alternative to thrombolytics, although its 
role is even less well defined than fibrinolytics. Local exper-
tise and availability are likely to dictate the initial choice be-
 Coenraad F.N. Koegelenberg 
 Division of Pulmonology, Department of Medicine 
 University of Stellenbosch and Tygerberg Academic Hospital 
 PO Box 19063, Tygerberg, Cape Town 7505 (South Africa) 
 Tel. +27 21 938 9423, Fax +27 21 933 3591, E-Mail coeniefn@sun.ac.za 
 © 2008 S. Karger AG, Basel
0025–7931/08/0753–0241$24.50/0 
 Accessible online at:
www.karger.com/res 
Previous articles in this series: 1. Froudarakis ME: Diagnos-
tic work-up of pleural effusions. Respiration 2008;75:4–13. 2. Jantz 





 Epidemiology and Risk Factors 
 Complicated parapneumonic effusions and empyema 
are more common at both extremes of age  [2, 3] . At least 
two thirds of patients will have an identifiable risk factor 
at presentation  [2] , which may include immunosuppres-
sive states (most frequently HIV infection, diabetes mel-
litus and malnutrition), alcohol or intravenous drug 
abuse, bronchial aspiration, poor dental hygiene, gastro-
oesophageal reflux, and chronic parenchymal lung dis-
ease  [3, 4] . Microbial virulence and idiosyncrasies of the 
immune system are often also implicated, principally in 
individuals with no apparent predisposition.
 Pathogenesis 
 Although pleural infection may occur as a primary 
event, most cases of pleural sepsis are secondary to pneu-
monias, lung abscesses or infective exacerbations of bron-
chiectasis. It should be noted that the associated pulmo-
nary consolidation may be minimal  [2] . Other identifi-
able causes include thoracic surgery, diagnostic proce-
dures involving the pleural space, trauma, oesophageal 
rupture, transdiaphragmatic spread and rarely bronchial 
obstruction  [5] . Primary pleural infections are presum-
ably most often due to the haematogenous spread of or-
ganisms from gingival and upper respiratory tract infec-
tions (with cultures yielding oropharyngeal flora and an-
aerobes)  [2, 6] or due to  Mycobacterium tuberculosis  [7] .
 The development of a parapneumonic effusion occurs 
in three clinically relevant stages that represent a con-
tinuous spectrum  [1, 8] . A rapid influx of exudative fluid 
into the pleural space is observed in up to 40% of patients 
with pneumonia and heralds the first or exudative stage 
 [1, 2] . The accumulation of fluid is thought to be a direct 
result of increased pulmonary interstitial fluid traversing 
the pleura to enter the pleural space  [1] and an increase 
in vascular permeability secondary to pro-inflammatory 
cytokines  [2, 9] , e.g. interleukin-8 and tumour necrosis 
factor-  . During this stage pleural fluid culture is nega-
tive for bacteria, fluid pH is  1 7.20, the glucose level is 
within the normal range and lactate dehydrogenase re-
mains  ! 3 times the upper limit of normal  [1, 2] . Most 
patents with uncomplicated parapneumonic effusions 
will respond to antibiotics alone and drainage is gener-
ally not required  [1, 2, 10] . 
 Untreated exudative effusions may develop into fibri-
nopurulent effusions. This second stage is characterized 
by positive microbial cultures. Ongoing phagocytosis 
and cell lysis result in fluid that most frequently has a
pH of  ! 7.20, a lactate dehydrogenase  1 3 times the upper 
limit and a low glucose  [1, 2, 10] . Rarely, fibrinopurulent 
effusions can have a pH in the normal or even in the al-
kaline range. This phenomenon is limited to a few patho-
gens (e.g.  Proteus spp.) with enzymatic activity that can 
elevate fluid pH, for instance by cleaving urea into am-
monia  [11] . During the fibrinopurulent stage the pleural 
space becomes increasingly infected. Loculations may 
develop and closed or open drainage becomes neces-
sary – the point in time where an effusion is referred to 
as ‘complicated’. A critical characteristic of the fibrino-
purulent stage of pleural sepsis is the disturbance of the 
physiological equilibrium between clotting and fibrino-
lysis within the pleural space  [2, 12] . Several mediators for 
the activation of the coagulation cascade and inhibition 
of fibrinolysis have been suggested: TNF-  , for example, 
has been shown to stimulate the release of plasminogen 
activator inhibitors from pleural mesothelial cells. Ale-
man et al.  [13]  were able to show increased levels of plas-
minogen activator inhibitor-2 and depressed levels of 
 tissue plasminogen activator (tPA) during complicated 
pleural sepsis. Although the exact mechanisms behind 
the procoagulate state still need to be elucidated, its ef-
fects are well-known: pleural surfaces coated with fibrin 
and fibrin strands with secondary adhesions and locula-
tions, all complicating pleural fluid drainage.
 The third and final stage of pleural infection is the or-
ganizing phase  [1, 2] . Fibroblasts grow into the pleural 
space from both the visceral and parietal pleura. This 
eventually results in a thick pleural peel, which restricts 
chest mechanics and often necessitates a surgical decor-
tication to address restrictive impairment. Recent re-
search on animal models has suggested a cardinal role for 
transforming growth factor-  1 as a fibrogenic cytokine 
in the development of pleural fibrosis  [14] .
 Bacteriology 
 The reported bacteriology of pleural sepsis varies sig-
nificantly between community-acquired and nosocomi-
al infections  [2] . Maskell et al.  [15]  reported the large pro-
spective MIST 1 trial (Multicenter Intrapleural Sepsis 
Trial 1) in 2005. Their study included 430 subjects across 
52 centres in the United Kingdom. Of these, 232 (54%) 
had positive pleural cultures. The  Streptococcus milleri 
group was the most common pathogen (29%), followed 
by staphylococci (21%) and  Streptococcus pneumoniae 
(16%). Anaerobes were isolated in 15%. Other isolates in-
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cluded other streptococci,  Haemophilus influenzae , en-
terobacteria,  M.  tuberculosis , and  Nocardia . The same in-
vestigators previously reported that nosocomial pleural 
infections were most commonly caused by methicillin-
resistant  Staphylococcus aureus (27%), other staphylococ-
ci (22%) and enterobacteria (20%)  [16] .
 Clinical Presentation 
 The presenting symptoms of complicated parapneu-
monic effusions and empyema can vary significantly and 
can be dominated by the preceding infective process. Im-
munocompetent patients with aerobic infections tend to 
be more acutely ill, and the clinical presentation is similar 
to pneumonia. This is followed by a ‘non-resolving pneu-
monia’ picture with pleuritic chest pain, fever spikes and 
a failure to improve on apparently adequate antibiotic 
therapy. Elderly individuals, immunocompromised pa-
tients and those with anaerobic infections can have a 
more indolent course, and may present with weight loss, 
cough, unexplained fever and anaemia  [1] .
 Diagnosis 
 Imaging 
 The chest radiograph usually shows a small to moder-
ate pleural effusion with or without parenchymal infil-
trates ( fig. 1 a). There may be evidence of loculations and 
air-fluid levels. Longstanding empyema may sometimes 
cause isolated rounded pleural opacities, which may be 
 Fig. 1. A series of images obtained from the same patient who pre-
sented with a complicated parapneumonic effusion.  a The chest 
radiograph: note the inhomogeneous nature of the left-sided 
opacity, the absence of the associated costophrenic angle, and the 
apparent air lucencies within the opacity.  b A thoracic US re-
vealed a classic septated complicated parapneumonic effusion. 
Note the strands of echogenic material within the loculations.
L = Loculations; S = septae.  c A chest CT scan did not show any 
loculations within the pleural fluid collection. Note the underly-
ing pulmonary consolidation that was not apparent on the chest 




confused with malignant pathology. It was once consid-
ered standard practice to request a lateral decubitus ra-
diograph on all patients with suspected pleural sepsis and 
to use the lateral thickness of the effusions on these films 
to guide the decision on the need for a thoracentesis  [1, 2] . 
Light et al. [17] showed that pleural effusions less than
1 cm thick on these radiographs resolved with antibiotic 
therapy alone and did not require pleural aspiration tho-
racentesis. Thoracic ultrasound (US), however, is an at-
tractive alternative to a lateral decubitus film, as it can 
very accurately measure the extent of pleural effusions 
and yields significantly more information regarding the 
state of the pleural space  [18, 19] .
 The routine use of thoracic US in patients with sus-
pected pleural sepsis should be encouraged. US is par-
ticularly helpful in determining the nature of localized or 
diffuse pleural opacities, and is more sensitive than decu-
bitus expiratory films in identifying small or loculated 
effusions  [18, 19] . Complicated parapneumonic effusions 
are associated with floating strands of echogenic mate-
rial which shows mobility with the respiration cycle and 
denotes advancing stage and chronicity. Complicated ef-
fusions may be subdivided into either septated or non-
septated effusions ( fig. 1 b). The presence of septae is clin-
ically relevant: Chen et al.  [20] demonstrated that patients 
with septated effusions needed longer chest tube drain-
age, longer hospital care, and were more likely to require 
fibrinolytic therapy or surgery compared with those with 
unseptated effusions. Tu et al.  [21]  confirmed these find-
ings in medical intensive care unit patients. Empyema 
with high viscosity may cause a strongly echogenic effu-
sion that can be mistaken for a solid pleural lesion. A 
change in shape during respiratory excursion and the 
presence of movable strands or echo densities are signs in 
favour of empyema  [22] . Furthermore, thoracic US is in-
valuable in guiding pleural aspirations and drainage and 
is superior to chest radiographs at identifying the optimal 
site for diagnostic thoracentesis  [23] . The success rate of 
US-guided thoracentesis can be as high as 97%. US guid-
ance also decreases the risk of complications following 
pleural procedures  [24] . 
 A thoracic computed tomography (CT) scan may be 
indicated to better delineate pulmonary and pleural anat-
omy, particularly if there is a suspicion of an alternative 
diagnosis (e.g. bronchogenic carcinoma) or prior to sur-
gical intervention  [25] . It should be appreciated that locu-
lations within a collection are best appreciated on US, 
and often not seen on a chest CT scan ( fig. 1 c). However, 
collections in interlobar spaces and those adherent to the 
paramediastinal pleura may escape detection by US and 
may only be visible on a CT scan (fig. 2: the small para-
vertebral collection will not be detected on ultrasound). 
Thickening of the parietal pleura ( fig. 2 ) on a contrasted 
CT scan is suggestive of empyema  [26] and thus an indi-
cation for thoracentesis, even in the presence of relatively 
small pleural collections. 
 Diagnostic Thoracentesis 
 All but small ( ! 10 mm on US or lateral decubitus radio-
graph), free-flowing parapneumonic effusions should be 
aspirated for diagnostic purposes  [27] . Apart from the rou-
tine chemistry, cytology and cell count analysis fluid 
should be sent off for a Gram stain and culture, and pleural 
fluid pH should be measured by means of a blood gas ma-
chine (not a pH meter or an indicator strip)  [1] . A positive 
result from either the Gram stain or culture, or a pH of 
 ! 7.20 is associated with a worse outcome and indicates the 
need for drainage  [27, 28] . If the pleural fluid pH is unavail-
able, the pleural fluid glucose may serve as a surrogate. A 
glucose level  1 3.4 mmol/l (60 mg/dl) is associated with a 
better prognosis  [1] . Pleural fluid adenosine deaminase is 
usually elevated in bacterial parapneumonic effusions and 
empyema, which are neutrophilic in nature. In the setting 
of a lymphocytic effusion, however, an elevated pleural ad-
enosine deaminase is highly suggestive of a tuberculous 
effusion, even in low prevalence areas  [25, 29, 30] .
L
S
 Fig. 2. A CT scan of a patient with empyema showing marked 
pleural thickening with enhancement, as well as volume loss of 
the left hemithorax (L, large collection). Also note the second, 
much smaller, left paravertebral pleural collection (S).  
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 Management 
 Principles 
 The treatment options for parapneumonic effusions 
range from non-invasive antibiotic therapy and observa-
tion, to semi-invasive techniques such as therapeutic 
 aspiration, tube thoracostomy and intrapleural fibrino-
lytics, to invasive interventions such as thoracoscopy, 
thoracotomy or open drainage  [1] . In practical terms, 
however, the initial evaluation should focus on three crit-
ical questions, namely: (1) Should the pleural space be 
drained? (2) How should the pleural space be drained? (3) 
Should fibrinolytics be instilled?  Table 1 is adapted from 
the American College of Chest Physicians’ (ACCP) con-
sensus statement that categorizes parapneumonic effu-
sions according to the need for drainage  [25] . It is impor-
tant to realize that the pleural space anatomy (best visu-
alized by means of US), pleural fluid appearance and 
smell, as well as pleural pH are often the only useful cri-
teria for initial decision making, as all other laboratory 
tests need time for processing. Frank pus on aspiration, 
large effusions greater than half of one hemithorax, effu-
sions with loculations (see  fig. 2 ), or fluid with a pH  ! 7.20 
all herald the need for immediate drainage. Further indi-
cations include a positive Gram stain, a positive micro-
bial culture and pleural fluid glucose of  ! 3.4 mmol/l (60 
mg/dl).
 Antibiotics 
 The initial antibiotic cover of patients with parapneu-
monic effusions is generally dictated by treatment guide-
lines for pneumonia, and is altered according to blood 
and pleural fluid microbial cultures and antibiotic sensi-
tivities. Empirical anaerobic antibiotic cover is generally 
advised  [2] , as there may be an anaerobic co-infection 
which is generally not as amenable to culture as aerobes. 
Choices in community-acquired empyema include intra-
venous amoxycillin with clavulanic acid or a combina-
tion of a second generation cephalosporin (e.g. cefurox-
ime) and metronidazole  [31] . Clindamycin monotherapy 
is an effective alternative for patients with a   -lactam al-
lergy. Patients with nosocomial empyema need adequate 
Gram-negative cover. Possible choices include carbapen-
ems, antipseudomonal penicillins (e.g. piperacillin/tazo-
bactam), or third or fourth generation cephalosporins 
(e.g. ceftazidime, cefepime) with metronidazole  [31] . Van-
comycin, linezolid or alternatives may have to be added 
for suspected or proven methicillin-resistant  S. aureus 
infections. Aminoglycosides demonstrate poor pleural 
penetration and reduced efficacy in acidic environments 
and should thus be avoided  [32] .
 Observation  
 ACCP category 1 ( table 1 ) effusions may be observed 
without a diagnostic aspiration, as the risk of a compli-
cated course is remote  [11] . All other cases require at least 
a diagnostic pleural aspiration before this decision can be 
made: only category 2 effusions may be observed without 
formal drainage. There should be no delay in draining 
category 3 and 4 effusions, as a free-flowing effusion may 
become loculated in a matter of 1 day. 
Table 1. Risk of poor outcome in patients with parapneumonic effusions and empyema
Cate-
gory 
Pleural space anatomy Pleural fluid 
chemistry
Pleural fluid bacteriology Risk of poor 
outcome
Drainage
1 Minimal, free-flowing effusion (<10 mm) and pH unknown and Gram stain and culture 
results unknown
very low no
2 Small to moderate free-flowing effusion 
(≥10 mm and <½ hemithorax)
and pH ≥7.20 and negative Gram stain and 
culture 
low no
3 Large, free-flowing effusion (≥½ hemithorax), 
loculated effusion, or effusion with thickened 
parietal pleura
or pH <7.20 or positive Gram stain and/
or culture
moderate yes
4 Empyema pus high yes 
Adapted from the American College of Chest Physicians’ consensus statement on the Medical and Surgical Treatment of Para-




 Therapeutic Thoracentesis 
 A once-off US-guided therapeutic thoracentesis is
an initial treatment option for moderately sized effu-
sions involving less than one hemithorax, in the absence 
of empyema or a pH  ! 7.20. It may serve as both diag-
nostic and, if no re-accumulation occurs, definitive 
management. Recurrent therapeutic pleural aspirations 
for empyema or complicated parapneumonic effusions 
have been largely abandoned, although Simmers et al. 
 [23]  showed that they were able to successfully treat 24 
of 29 patients with parapneumonic effusions by means 
of alternate day US-guided pleural aspirations. Major 
disadvantages of this technique seem to be the high 
number of necessary aspirations and the long hospital 
stay, as a mean of 7.7 aspirations in 31 days was needed 
in their study.
 Tube Thoracostomy 
 Indications for chest tube drainage include empyema, 
complicated parapneumonic effusions (pH  ! 7.20, locula-
tions or positive bacteriological investigations) and large 
effusions (more than half of a hemithorax involved)  [27] . 
This is most commonly achieved by a standard (24–28 
french) intercostal chest drain that is positioned in the 
dependent part of a free-flowing pleural effusion (most 
often the posterior costophrenic recess). Insertions are 
best guided by US, as thickened parietal pleura, adhe-
sions or loculations often complicate insertion. Common 
sense suggests that smaller bore drains are likely to fail in 
the presence of pus with a high viscosity. However, some 
prospective studies have found that 8- to 12-french pig-
tail catheters or 10- to 14-french catheters inserted with 
the Seldinger technique under US or CT guidance were 
at least as effective as larger catheters inserted without 
imaging  [33–35] . However, the positioning of the catheter 
tips with guidance is likely to be superior compared to 
blind insertion, irrespective of drain size. Most of these 
studies also employed a strict rinsing schedule (often sev-
eral times a day), which might be difficult to sustain in 
everyday clinical practice. Moreover, a very recent study 
found a failure rate of 19% with small-bore catheters and 
concluded that the threshold for using fibrinolytics and 
large-bore catheters should be low in empyema  [36] .
 Thrombolytics 
 Complicated parapneumonic effusions and empy-
emas are characterized by a procoagulant state within the 
pleural space which results in the progressive develop-
ment of dense layers of fibrin and loculations. It therefore 
seems highly plausible that intrapleural fibrinolytics giv-
en early in the fibronopurulent phase should prevent loc-
ulations and promote pleural drainage. In fact, Tillett 
and Sherry  [37]  described the use of streptokinase and 
streptodornase for this very indication as early as 1949. 
Unjustified fears of systemic side effects and a paucity of 
controlled clinical trials have unfortunately delayed the 
compilation of an evidence base for the use of this modal-
ity for many years.
 Numerous case series and controlled trials have shown 
that intrapleural fibrinolysis is safe, increases drainage 
and improves radiological appearance. A randomized 
controlled study by Davies et al.  [38] established that sys-
temic fibrinolysis or bleeding complications did not oc-
cur with streptokinase, and that patients who were given 
intrapleural streptokinase drained significantly more 
pleural fluid both during the days of treatment (n = 24; 
mean 391 vs. 124 ml, p  ! 0.001) and overall. Patients who 
received fibrinolytics also showed greater improvement 
on the chest radiograph at discharge.
 Bouros et al.  [39]  demonstrated that urokinase was a 
safe intrapleural fibrinolytic. The same group showed 
that streptokinase and urokinase were clinically and ra-
diologically equally effective as intrapleural fibrinolytics 
 [40] , and that intrapleural urokinase decreased the dura-
tion of hospitalization, duration of pleural drainage and 
time to defervescence. Furthermore, Bouros et al.  [41] 
 were able to show that urokinase’s effect in empyema was 
through the lysis of pleural adhesions, rather than the 
volume effect of instilled urokinase and saline. 
 Lim and Chin  [42]  evaluated the efficacy of three dif-
ferent treatment protocols, namely simple chest tube 
drainage, adjunctive intrapleural streptokinase, and an 
aggressive empirical approach incorporating streptoki-
nase and early surgical drainage in patients with pleural 
empyema and high-risk parapneumonic effusions. In 
this non-randomized, prospective, controlled series they 
found that the average duration of hospital stay and mor-
tality in both the streptokinase and early surgical drain-
age group was significantly shorter than with tube drain-
age alone. The authors concluded that an empirical treat-
ment strategy which combines adjunctive intrapleural 
fibrinolysis with early surgical intervention resulted in 
shorter hospital stays and possible reduced mortality in 
patients with pleural sepsis.
 The most meaningful clinical endpoint, that of the 
necessity for surgical intervention, was only recently ad-
dressed in randomized controlled studies. Tuncozgur et 
al.  [43]  found a significantly lower decortication rate (60 
vs. 29.1%, p  ! 0.01) and shorter duration of hospitaliza-
tion (14 vs. 21 days, p  ! 0.01) with urokinase than with 
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placebo. A single-centre, randomized, placebo-con-
trolled study by Diacon et al.  [44] used structured clini-
cal protocols for inclusion and evaluation and demon-
strated that intrapleural streptokinase resulted in faster 
resolution of infection, reduced need for surgery (13.6 
vs. 45.5%, p = 0.018) and improved clinical outcome in 
patients with loculated parapneumonic effusions and 
empyema.
 The largest prospective double-blind controlled study 
on the role of intrapleural streptokinase for pleural in-
fection was published in 2005 (MIST 1)  [15] . In this study 
454 patients with pleural pus, pleural sepsis with a pH 
 ! 7.2 or bacterial invasion of the pleural space were ran-
domly assigned to receive streptokinase or placebo. The 
patients included were older than in most other studies 
(average age 60 years) and had a high prevalence of co-
morbidities. The MIST 1 study could not substantiate the 
role of streptokinase in pleural infections: There was no 
difference in mortality, need for surgery, radiographic 
outcome or length of hospitalization. The design and ex-
ecution of this study, however, were criticized  [45–47] . 
The lack of image-based selection criteria meant that pa-
tients with pleural sepsis were included irrespective of 
presence, quantity and quality of loculations. Questions 
were raised about the reproducibility of clinical manage-
ment decisions taken across 52 study centres, many of 
which lacked on-site surgical expertise and contributed 
only small numbers of patients. The study permitted 
small-bore chest tubes, but did not report on pleural 
drainage volumes, which casts doubt on the efficacy of 
the drainage techniques used. Furthermore, owing to 
the decentralized and blinded design streptokinase/pla-
cebo was shipped to the study centres after randomiza-
tion causing delays in the initiation of treatment. The 
value of mortality as an endpoint was also questioned, as 
patients with serious concomitant illnesses that made 
survival beyond 3 months unlikely were excluded from 
the study. The 3-month mortality after hospitalization 
for pneumonia among middle-aged and older patients is 
more closely associated with the fact that an episode of 
pneumonia often identifies a fragile underlying health 
status than with the severity of the acute episode of pneu-
monia itself  [45] . Intrapleural streptokinase may there-
fore not have been given a fair chance to improve the 
short-term mortality  [45] . These deficiencies do not in-
validate this large randomized trial, but concerns remain 
about the validity of its results with regards to younger, 
more severely ill patients and in different health care set-
tings. 
 The most recent and second largest prospective study 
was conducted by Misthos et al.  [48] . In their study pa-
tients were randomized to a group managed solely with 
tube thoracostomy or a group treated with a combina-
tion of tube thoracostomy and streptokinase instillation 
(no placebo control). They found that tube thoracostomy 
was successful in 67.1% of cases, whereas the installation 
of streptokinase led to a favourable outcome in 87.7%
(p  ! 0.05) and significantly shortened hospital stay. The 
mortality rate was also significantly lower in the fibrino-
lytic group, and streptokinase was found to decrease the 
rate of surgical interventions and the length of hospital 
stay.
 Tokuda et al.  [49]  published a meta-analysis of all the 
major placebo-controlled studies on intrapleural fibrino-
lysis  prior to publication of the study by Misthos et al. 
Albeit they were able to demonstrate a trend towards im-
proved survival and a decreased need for surgical inter-
ventions, the differences failed to become statistically sig-
nificant.
 Clinical trials on the efficacy of recombinant tPA and 
DNase are currently being performed. An interesting ex 
vivo observation by Light et al.  [50]  was that DNase com-
bined with streptokinase (known as Varidase) was supe-
rior to either streptokinase or urokinase at liquefying em-
pyemic pleural material obtained from rabbits. It was 
postulated that the streptodornase (DNase) was neces-
sary for the liquefaction of the deoxyribose nucleopro-
teins, which make up a sizable proportion of the solid 
sediment of purulent exudates .
 In conclusion, current evidence suggests that intra-
pleural fibrinolytics cannot be recommended as the stan-
dard treatment of parapneumonic effusion and empy-
ema. There seems to be a place for fibrinolytics in the 
early management of loculated (complicated) parapneu-
monic effusions and empyema, particularly in young, 
acutely ill patients, poor surgical candidates and in cen-
tres where surgical facilities are limited. Streptokinase 
and urokinase are presumably equally effective and safe. 
The efficacy of tPA and DNase still needs to be estab-
lished. The suggested dosages of the current fibrinolytics 
in use are summarized in  table 2 .
 Thoracoscopy 
 Thoracoscopy remains a treatment option for the pa-
tient with an incompletely drained loculated parapneu-
monic effusion, provided that it is performed early in the 
disease and that the pleural anatomy is defined by means 
of either US or CT scan  [51, 52] . Loculations can be bro-




and an intercostal chest tube can be optimally placed  [1] . 
Furthermore, visual inspection of the pleura may guide 
decisions regarding the need for an open surgical proce-
dure  [1] .
 The exact point where thoracoscopy becomes useful 
in the management of pleural sepsis remains unclear and 
is even less well defined than the role of fibrinolytics. Sev-
eral small retrospective and unblinded prospective stud-
ies suggest that thoracoscopy is superior to fibrinolysis 
 [51–54] , with the need for thoracotomy or thoracostomy 
almost halved  [53] . At least one study performed on a pae-
diatric population, however, found urokinase to be more 
cost-effective than routine thoracoscopy  [55] . Practically 
all prospective studies on the role of thoracoscopy  [51, 
53–55] utilized video-assisted thoracoscopy (VATS), as 
opposed to medical thoracoscopy. Current evidence does 
not allow a clear choice between the modalities, and local 
expertise is likely to dictate the preferred method.
 Surgical Management 
 Open surgery may be required at various stages of the 
evolution of complicated parapneumonic effusions or 
empyema. The aim of a procedure in the subacute phase 
is usually to control sepsis, whereas a procedure in the 
chronic phase aims to restore chest mechanics by remov-
ing a restrictive fibrotic peel encasing the lung ( fig. 3 ).
 The main indications for open surgical drainage are 
failure of medical management to control sepsis in the 
acute stages of pleural sepsis and failure of tube thora-
costomy or thoracoscopy to yield reexpansion of the 
lung  [1, 56] . Thoracotomy with drainage and subsequent 
closure of the chest with one or more drains left in situ 
is the standard procedure. Thoracostomy involves inci-
sion through the chest wall with rib resection, which 
produces a stoma with continuous drainage of the chest 
cavity. In addition, one or more chest tubes can be in-
serted through the opening, and irrigated daily. The 
chest tubes can gradually be retracted until complete re-
moval, a process that takes 2–3 months to complete. 
Drainage from the thoracostomy or from the tubes (cut 
off close to the skin) can be collected in a colostomy bag. 
A different approach involves packing the empyema cav-
ity with gauze. A more complex procedure may be per-
formed when the tract between the pleural cavity and the 
surface of the chest is lined with a skin and muscle flap 
following rib resection  [1] . Drainage is thus achieved 
without chest tubes with gradual obliteration of the em-
pyema cavity  [57] .
 Decortication is a major surgical intervention that en-
tails the excision of all fibrous tissue from the pleura, with 
or without the evacuation of associated pus and debris 
Table 2. Intrapleural fibrinolytics – practical use
Fibrinolytic Dose Instillation1 Duration 
Streptokinase 250,000 IU 100–200 ml saline daily for up to 7 days (until drainage <100 ml/day) 
Urokinase2 100,000 IU 100 ml saline daily for up to 3 days 
tPA   10–25 mg 100 ml saline twice daily for up to 3 days 
1 Drain should be clamped for approximately 2 h following installation of fibrino lytics.
2 Urokinase is no longer universally available.
Fig. 3. A chest radiograph showing the long-term sequelae of em-
pyema. Note the formation of a thick pleural peel with volume loss 
and incarceration of the left lung causing restrictive impair-
ment.
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from the pleural cavity, in order to permit lung reexpan-
sion  [58] . It remains a procedure with significant morbid-
ity and a reported mortality of up to 10%  [59] . As pleural 
thickening may resolve over time, decortication is best 
deferred for up to 6 months  [60] . 
 Conclusions: Suggested Management of 
Parapneumonic Effusions and Empyema 
 All patients with parapneumonic pleural effusions 
and empyema require early and adequate antibiotic treat-
ment. Thoracic US should be performed on patients with 
suspected parapneumonic effusion that is not clearly vi-
sualized on a routine postero-anterior chest radiograph. 
Small, unseptated and free-flowing effusions may be ob-
served, but all other effusions warrant an urgent diagnos-
tic thoracentesis. Sterile effusions with a pH  6 7.20 may 
be observed on antibiotic cover. Empyema and large or 
loculated effusions need to be drained, as well as para-
pneumonic effusions with a pH  ! 7.20, glucose  ! 3.4 
mmol/l or positive microbial stain and/or culture. 
 An US-guided therapeutic thoracentesis is an elegant 
initial treatment option for uncomplicated effusions of 
moderate size, in the absence of empyema or a pH  ! 7.20, 
loculations or positive bacteriological investigations. It 
may serve both as a diagnostic and, if no reaccumulation 
occurs, definitive procedure. The US evaluation of the 
pleural cavity will also guide further management. Large 
bore tube thoracostomy is the treatment option of choice 
for patients with empyema. Parapneumonic effusions 
that recur following a single aspiration or cases at high 
risk should be drained by means of either standard or 
small-bore intercostal drains.
 The use of fibrinolytics remains controversial, al-
though evidence suggests a role for the early use in com-
plicated, loculated parapneumonic effusions and empy-
ema, particularly in young, acutely ill patients, poor sur-
gical candidates and in centres with inadequate surgical 
facilities. Early thoracoscopy is an alternative to throm-
bolytics. Local expertise and availability will to a certain 
extent dictate the initial choice between tube thoracos-
tomy with fibrinolytics or thoracoscopy, although thora-
coscopy may also be performed following fibrinolytics if 
complete drainage is not achieved.
 An open surgical drainage procedure will be required 
for complete drainage where tube thoracostomy or tho-
racoscopy with associated medical management fails to 
control pleural sepsis. A surgical decortication may be 
needed to remove a thick pleural peal and to restore chest 
mechanics, but this procedure is best deferred for at least 
6 months. 
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